Publications Database

Matson J. L. , Hess J. A. (2011)

Psychotropic drug efficacy and side effects for persons with autism spectrum disorders.

Research in Autism Spectrum Disorders

51

Read Abstract (New Window)

McCracken J. T. et al. (2002)

Risperidone in children with autism and serious behavioral problems.

New England Journal of Medicine

347(5), pp. 314-321

Read Abstract (New Window) Read Full (New Window)

McDougle C. J. , Kem D. , Posey D. J. (2002)

Case series: use of ziprasidone for maladaptive symptoms in youths with autism.

Journal of the American Academy of Child and Adolescent Psychiatry

41(8), pp. 921-927

Read Abstract (New Window)

Mouridsen S. E. , Rich B. , Isager T. (2008)

Body mass index in male and female children with pervasive developmental disorders.

Pediatrics International

50(4), pp. 569-571.

Read Abstract (New Window)

Mukaddes N. M. , Abali O. , Gurkan K. (2004)

Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).

World Journal of Bilogical Psychiatry

5(4), pp. 211-214

Read Abstract (New Window)

Nagaraj R. , Singhi P. , Malhi P. (2006)

Risperidone in children with autism: randomized, placebo-controlled, double-blind study.

Journal of Child Neurology

21(6), pp. 450-455

Read Abstract (New Window)

Nicolson R. , Awad G. A. , Sloman L. (1998)

An open trial of risperidone in young autistic children.

Journal of the American Academy of Child and Adolescent Psychiatry

37(4), pp. 372-376

Read Abstract (New Window)

Potenza M. et al. (1999)

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

Journal of Clinical Psychopharmacology

19(1), pp. 37-4.

Read Abstract (New Window)

Scahill L. et al. (2016)

Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

May, 55(5), pp. 415-423.

Read Abstract (New Window)

Schreier H. (1998)

Risperidone for young children with mood disorders and aggressive behavior.

Journal of Child and Adolescent Psychopharmacology

8(1), pp. 49-59

Read Abstract (New Window)

Scott L. , Dhillon S. (2008)

Spotlight on risperidone in irritability associated with autistic disorder in children and adolescents.

CNS Drugs

22(3), pp. 259-262

Read Abstract (New Window)

Silva R. R. et al. (1993)

Haloperidol withdrawal and weight changes in autistic children.

Psychopharmacology Bulletin

29(2), pp. 287-291

Read Abstract (New Window)

Sochocky N. , Milin R. (2013)

Second generation antipsychotics in Asperger's disorder and high functioning autism: A systematic review of the literature and effectiveness meta-analysis.

Current Clinical Pharmacology

8(4), pp. 370-379.

Read Abstract (New Window)

Stachnik J. M. , Nunn-Thompson C. (2007)

Use of atypical antipsychotics in the treatment of autistic disorder.

Annals of Pharmacotherapy

41(4), pp. 626-634

Read Abstract (New Window)

Stigler K. A. , Posey D. J. , McDougle C. J. (2004)

Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder.

Journal of Child and Adolescent Psychopharmacology

14(3), pp. 455-463

Read Abstract (New Window)

Stigler K. A. et al. (2004)

Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.

Pediatric Drugs

6(1), pp. 33-44

Read Abstract (New Window)

Troost P. et al. (2005)

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.

Journal of the American Academy of Child and Adolescent Psychiatry

44(11), pp. 1137-1144

Read Abstract (New Window)

Wink L. K. et al. (2017)

Brief report: Metformin for antipsychotic-induced weight gain in youth with autism spectrum disorder.

Journal of Autism and Developmental Disorders

July, 47(7), pp. 2290–2294.

Read Abstract (New Window)

Wise E. A. , Smith M. D. , Rabins P. V. (2017)

Aging and autism spectrum disorder: A naturalistic, longitudinal study of the comorbidities and behavioral and neuropsychiatric symptoms in adults with ASD.

Journal of Autism and Developmental Disorders

June, 47(6), pp. 1708–1715.

Read Abstract (New Window)

Zuddas A. et al. (2000)

Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.

Journal of Child and Adolescent Psychopharmacology

10(2), pp. 79-90

Read Abstract (New Window)